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Abstract: (1) Background: Oxidative stress and inflammation are associated with higher risk of
chronic kidney disease (CKD). Serum ferritin concentrations correlate with total iron levels and
systemic inflammation. (2) Methods: This study was cross-sectionally designed, based on the
2010–2012 Korean National Health and Nutrition Examination Survey (KNHANES). According to
ferritin values, 13,462 participants (6082 men and 7380 women) were categorized into the normal- and
high-ferritin groups (cut-off points: 200 ng/mL in men, 150 ng/mL in women). (3) Results:
The mean ages of men and women were 44.5 and 48.4 years, respectively. The percentage of
participants categorized into the high-ferritin group was 15.1% for men and 3.6% for women.
The estimated glomerular filtration rate levels in the normal- and high-ferritin groups were 93.2
and 93.8 mL/min/1.73 m2 for men and 97.1 and 87.7 mL/min/1.73 m2 for women, respectively.
The prevalence of CKD in the normal- and high-ferritin groups was 2.6% and 3.9% for men and
3.2% and 8.1% for women, respectively. Compared with the normal-ferritin group, the odds ratios
(95% confidence intervals) for CKD of the high-ferritin group were 1.573 (1.014–2.441) in men
and 1.061 (0.381–2.955) in women, after adjustments for age and other covariates. (4) Conclusions:
High ferritin levels were associated with a higher risk of CKD in men but not in women.
Keywords: ferritin; oxidative stress; inflammation; chronic kidney disease; iron
1. Introduction
Chronic kidney disease (CKD) is becoming prevalent worldwide, affected by the global increase
of the aged population. The burden of CKD on public health is increasing in severity [1]. In addition
to aging, modifiable risk factors, such as obesity, cigarette-smoking, alcohol-drinking, and physical
inactivity, are widely known causes of CKD. Furthermore, oxidative stress and inflammation interact
with each other and can accelerate the development and progression of kidney injury [2].
The overloading of body iron plays a role as an oxidative stressor, which can convert less-reactive
free radicals to more-reactive hydroxyl radicals. These active radicals can affect lipids, proteins,
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and deoxyribonucleic acid (DNA), resulting in tissue injury and dysfunction [3]. Excess iron causes
oxidative stress and induces inflammation, leading to renal disease progression [4]. Serum ferritin
levels correlate with total body iron storage and systemic inflammation [5]. The level of serum
ferritin, an acute phase protein, is increased in an inflammatory environment [5]. Previous studies
have reported that elevated serum ferritin levels are associated with insulin resistance syndrome,
hypertension, dyslipidemia, obesity, and metabolic syndrome as risk factors of CKD [6–10].
Furthermore, elevated serum ferritin levels in hemodialysis patients predict higher mortality [11].
However, there is a lack of evidence whether serum ferritin levels are associated with risk of CKD.
The aim of this study is to investigate the associations between serum ferritin levels




The Korean Ministry of Health and Welfare conducts the KNHANES, a nationwide survey
representing the entire Korean population. The sampling units were chosen as households using
a stratified, multistage, probability-sampling design according to geographic area, sex, and age
group, based on household registries. Participants were requested to answer a health interview
survey including a health behavior questionnaire, health examination questionnaire, and nutrition
questionnaire. Trained interviewers conducted the health interview survey through one-on-one
interviews at the participants’ houses. The National Health Enhancement Act guarantees the
citizens’ right to refuse to participate in this survey. All procedures performed in studies involving
human participants were in accordance with the ethical standards of the institutional and/or
national research committee and with the 1964 Helsinki Declaration and its later amendments
or comparable ethical standards. All participants in the survey were provided written informed
consent. The KNHANES was approved by the Institutional Review Board of the KCDC (IRB No:
2008-04EXP-01-C, 2009-01CON-03-2C, 2010-02CON-21-C, 2011-02CON-06C), and written informed
consent was collected from all of the participants before the KNHANES. The Korea Center for
Disease Control and Prevention acquired participant approval for the further use of blood samples for
academic research.
We excluded participants younger than 20 years, those who had incomplete laboratory data,
and those whose ferritin level was lower than 15 ng/mL. After these exclusions, 13,462 individuals
(6082 men and 7380 women) were included in the final analysis. The Institutional Review Board of the
Korea Centers for Disease Control and Prevention approved this study.
2.2. Measurement of Anthropometry and Laboratory Data
Trained medical staff conducted physical examinations following standard protocols. Body weight
and height were measured to the nearest 0.1 kg and 0.1 cm, respectively, with subjects wearing light
indoor clothing without shoes. Blood pressure was measured twice on the right arm at five-minute
intervals using a mercury sphygmomanometer (Baumanometer; Baum, Copiague, NY, USA) and was
charted as a mean value. After participants fasted overnight, blood samples were collected from the
antecubital vein. The levels of fasting plasma glucose, cholesterol, alanine aminotransferase (ALT),
and creatinine were measured enzymatically using a Hitachi Automatic Analyzer 7600 (Hitachi, Tokyo,
Japan). White blood cell (WBC) counts were assessed using laser flow cytometry methods by XE-2100
(Sysmex, Kobe, Japan). Serum ferritin levels were measured by immunoradiometric assay using a
1470 WIZARD gamma-counter (PerkinElmer, Kurku, Finland). Dipstick urinalyses were conducted
with an Urisys 2400 (Roche, Mannheim, Germany).
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2.3. Definition of Ferritin Levels, Chronic Kidney Disease and Health Behavior
Participants with hypoferritinemia (<15 ng/mL) were excluded in order to avoid including
patients with anemia. The WHO indicated that ferritin levels over 200 ng/mL for men and 150 ng/mL
for women are associated with a severe risk of iron overload [12]. Ferritin levels were categorized
into two groups according to cut-off points (men: 200 ng/mL, women: 150 ng/mL): normal-ferritin
group, 15–200 ng/mL in men and 15–150 ng/mL in women; and high-ferritin group, >200 ng/mL in
men and >150 ng/mL in women [12]. An estimated glomerular filtration rate (eGFR) was calculated
using the abbreviated equation from the Modification of Diet in Renal Disease (MDRD) study: eGFR
(mL/min/1.73 m2) = 186.3 × (serum creatinine−1.154) × (age−0.203) × 0.742 (if female) [13]. CKD was
defined based on either renal tissue damage or reduced renal function as eGFR < 60 mL/min/1.73 m2
or proteinuria 1+ or greater [13]. Proteinuria was tested using a dipstick method with freshly voided
urine samples.
Information on health-related lifestyles was obtained from the data gathered from the self-report
questionnaire during the interview portion of each survey. Individuals who engaged in ≥20 min of
vigorous-intensity physical activity at least three days a week or≥30 min of light- to moderate-intensity
physical activity at least five days a week were categorized as the regular exercise group, using the
short form of the International Physical Activity Questionnaire [14]. To identify high-risk drinkers,
we used the Alcohol Use Disorders Identification Test (AUDIT) [15]. The cut-off points of the AUDIT
score were used to categorize participants into three groups: low-risk drinkers, 0–7; intermediate-risk
drinkers, 8–14; and high-risk drinkers, ≥15 points. Individuals who smoked cigarettes during the
relevant survey period were categorized as current smokers. Daily calorie intake was monitored by a
24-h food recall and analyzed using CAN-Pro 3.0 software (Korean Nutrition Society, Seoul, Korea).
2.4. Statistical Analysis
Data taken from the Korea National Statistical Office was used to define the standard population.
To represent the entire population of Korean adults with unbiased estimates, sampling weights were
applied to account for the complex sampling. All data from continuous variables are presented
as mean ± standard error (SE). Data from categorical variables are presented as percentage ± SE.
Student’s t-tests for continuous variables and Chi-squared tests for categorical variables were used to
compare the mean values and percentages according to ferritin level, respectively. The odds ratios (ORs)
and corresponding 95% confidence intervals (95% CIs) for prevalence risk of CKD were calculated
using weighted multivariate logistic regression analyses after adjusting for age and confounding factors.
All analyses were conducted using SPSS statistical software, version 21 (IBM, New York, NY, USA).
All statistical tests were two-tailed, and p-values less than 0.05 were considered statistically significant.
3. Results
Subject characteristics were presented in Table 1. The mean ages of men and women were
44.5 and 48.4 years old, respectively. The mean ferritin levels were 130.6 ng/mL in men and
57.7 ng/mL in women. The percentage of participants in the high-ferritin group was 15.1% for
men and 3.6% for women. The eGFR levels of men and women were 93.2 and 96.8 mL/min/1.73 m2,
respectively. The percentages of low eGFR and proteinuria were 2.0% and 1.2% in men and 2.3% and
1.2% in women, respectively. The prevalence of CKD was 2.8% in men and 3.4% in women.
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Table 1. Subject characteristics by sex.
Parameters Men Women
Unweighted N 6082 7380
Age (year) 44.5 ± 0.3 48.4 ± 0.3
BMI (kg/m2) 24.1 ± 0.58 23.6 ± 0.1
SBP (mmHg) 120.7 ± 0.3 117.1 ± 0.3
DBP (mmHg) 79.4 ± 0.2 74.2 ± 0.2
FPG (mg/dL) 98.6 ± 0.4 96.0 ± 0.3
Cholesterol (mg/dL) 188.2 ± 0.7 190.8 ± 0.6
ALT (IU/L) 27.2 ± 0.5 18.6 ± 0.3
Creatinine (mg/dL) 0.97 ± 0.003 0.72 ± 0.003
Ferritin (ng/mL) 130.6 ± 1.9 57.7 ± 0.8
Energy intake (kcal/day) 2461 ± 18 1686 ± 12
eGFR (mL/min/1.73 m2) 93.2 ± 0.3 96.8 ± 0.3
High-risk drinker (%) a 25.5 ± 0.8 4.8 ± 0.4
Ever smoker (%) a 76.2 ± 0.7 11.2 ± 0.5
Regular exerciser (%) a 50.0 ± 0.9 43.8 ± 0.8
High ferritin group (%) a 15.1 ± 0.6 3.6 ± 0.3
Low eGFR (%) a 2.0 ± 0.2 2.3 ± 0.2
Proteinuria (%) 1.2 ± 0.1 1.2 ± 0.2
Chronic kidney disease (%) 2.8 ± 0.2 3.4 ± 0.3
All data are presented as mean or percentage ± standard error (SE) and their p-values are determined by
independent t-tests and chi-square tests. a High-risk drinker: Alcohol Use Disorders Identification Test AUDIT
≥ 15; Ever smoker who had smoked at least 100 cigarettes; Regular exerciser: vigorous intensity ≥ 3 days
and/or moderate intensity≥ 5 days; High ferritin group: ferritin levels are≥200 ng/mL for men, 150 ng/mL for
women; Low eGFR < 60 mL/min/1.73 m2. Abbreviation: BMI, body mass index; SBP, systolic blood pressure;
DBP, diastolic blood pressure; FPG, fasting plasma glucose; ALT, alanine aminotransferase; eGFR, estimated
glomerular filtration rate.
Table 2 showed the subject characteristics according to ferritin levels. The high-ferritin group
had higher levels of BMI, blood pressure, fasting plasma glucose, cholesterol, and ALT in both
sexes. Female eGFR levels were lower in the high-ferritin group than the normal-ferritin group
(97.1 vs. 87.7 mL/min/1.73 m2, p-value < 0.001), while male eGFR levels did not differ significantly
between the groups (93.2 vs. 93.8 mL/min/1.73 m2, p-value = 0.404). The percentage of men having low
eGFR levels was 2.0% in the normal-ferritin group and 2.2% in the high-ferritin group (p-value = 0.636),
while that of women was 2.1% in the normal-ferritin group and 7.7% in the high-ferritin group
(p-value < 0.001). The proteinuria percentage in men was 0.9% in the normal-ferritin group and 2.6%
in the high-ferritin group (p-value < 0.001), while that of women were 1.2% in the normal-ferritin
group and 0.9% in the high-ferritin group (p-value = 0.582). The percentage of individuals with CKD
in both sexes was higher in the high-ferritin group than the normal-ferritin group (2.6% vs. 3.9% in
men, p-value = 0.032; 3.2% vs. 8.1% in women, p-value < 0.001).
Weighted logistic regression analyses were conducted to demonstrate the association between
ferritin levels and CKD risk, as shown in Table 3. Compared to the normal-ferritin group, OR (95% CI)
of the high-ferritin group was 1.590 (1.035–2.444) in men and 1.438 (0.895–2.312) in women after
being adjusted for age (Model 1). After adjustment for age, energy intake, drinking status, smoking
status, physical activity status, BMI, fasting plasma glucose, cholesterol, and ALT, the OR (95% CI) was
1.573 (1.014–2.441) in men and 1.061 (0.381–2.955) in women (Model 3). After further adjusting for WBC
counts as another inflammatory marker in addition to Model 3, the statistical significance of the OR
(95% CI) for CKD in men was attenuated (1.524 (0.995–2.335), p-value = 0.053) in Model 4. Additionally,
logistic regression analyses for CKD of various risk factors were conducted in Supplementary
Materials Table S1.
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Table 2. Subject characteristics according to ferritin levels.
Parameters Men p-Value Women p-Value
Ferritin levels 15–200 ng/mL >200 ng/mL 15–150 ng/mL >150 ng/mL
Unweighted N 5157 925 7050 330
Age (year) 44.3 ± 0.3 45.7 ± 0.6 0.026 47.9 ± 0.3 61.0 ± 0.9 <0.001
BMI (kg/m2) 23.9 ± 0.1 25.1 ± 0.1 <0.001 23.5 ± 0.1 25.1 ± 0.2 <0.001
SBP (mmHg) 120.2 ± 0.3 123.4 ± 0.6 <0.001 116.8 ± 0.3 126.7 ± 1.3 <0.001
DBP (mmHg) 79.0 ± 0.2 81.9 ± 0.5 <0.001 74.1 ± 0.2 76.3 ± 0.7 0.002
FPG (mg/dL) 97.5 ± 0.4 105.0 ± 1.0 <0.001 95.4 ± 0.3 112.1 ± 3.3 <0.001
Cholesterol (mg/dL) 187.1 ± 0.7 194.0 ± 1.7 <0.001 190.2 ± 0.6 204.9 ± 3.3 <0.001
ALT (IU/L) 24.1 ± 0.3 44.6 ± 2.7 <0.001 17.9 ± 0.2 36.6 ± 3.6 <0.001
Creatinine (mg/dL) 0.97 ± 0.003 0.96 ± 0.007 0.145 0.72 ± 0.003 0.78 ± 0.027 0.018
Ferritin (ng/mL) 97.2 ± 0.8 319.0 ± 8.0 <0.001 51.2 ± 0.5 230.4 ± 9.2 <0.001
Energy intake (kcal/day) 2452 ± 19 2517 ± 51 0.220 1692 ± 12 1520 ± 39 <0.001
eGFR (mL/min/1.73 m2) 93.2 ± 0.3 93.8 ± 0.7 0.404 97.1 ± 0.3 87.7 ± 1.4 <0.001
High-risk drinker (%) a 22.6 ± 0.8 41.8 ± 2.1 <0.001 4.8 ± 0.4 3.9 ± 1.6 0.624
Ever smoker (%) a 74.8 ± 0.8 84.1 ± 1.6 <0.001 11.2 ± 0.6 11.4 ± 2.4 0.934
Regular exerciser (%) a 51.1 ± 0.9 43.6 ± 2.1 0.001 44.0 ± 0.8 36.8 ± 3.6 0.054
Low eGFR (%) a 2.0 ± 0.2 2.2 ± 0.5 0.636 2.1 ± 0.2 7.7 ± 1.6 <0.001
Proteinuria (%) 0.9 ± 0.1 2.6 ± 0.6 <0.001 1.2 ± 0.2 0.9 ± 0.5 0.582
Chronic kidney disease (%) 2.6 ± 0.2 3.9 ± 0.7 0.032 3.2 ± 0.3 8.1 ± 1.7 <0.001
All data are presented as mean or percentage ± standard error (SE) and their p-values are determined by
independent t-tests and chi-square tests. a High-risk drinker: AUDIT ≥ 15; Ever a smoker who had smoked at
least 100 cigarettes; Regular exerciser: vigorous intensity ≥ 3 days and/or moderate intensity ≥ 5 days; Low
eGFR < 60 mL/min/1.73 m2; Abbreviation: BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic
blood pressure; FPG, fasting plasma glucose; ALT, alanine aminotransferase; eGFR, estimated glomerular
filtration rate.
Table 3. Odds ratios for chronic kidney disease according to ferritin levels.
Adjusted Models Men Women
Ferritin levels 15–200 ng/mL >200 ng/mL 15–150 ng/mL >150 ng/mL
Model 1 1 1.590 (1.035–2.444) 1 1.438 (0.895–2.312)
Model 2 1 1.703 (1.092–2.656) 1 1.435 (0.751–2.741)
Model 3 1 1.573 (1.014–2.441) 1 1.061 (0.381–2.955)
Note: Model 1 was adjusted for age; Model 2 was adjusted for age, energy intake, drinking status, smoking
status, and physical activity status; Model 3 was adjusted for age, energy intake, systolic blood pressure,
body mass index, fasting plasma glucose, total cholesterol, ALT, drinking status, smoking status, and physical
activity status.
4. Discussion
The major findings of this study are that serum ferritin levels were associated with a higher
prevalence risk of CKD in Korean men but not in Korean women.
The prevalence of CKD is increasing, especially in Westernized countries. Conventionally, aging,
elevated blood pressure, hyperglycemia, dyslipidemia, and obesity contribute to renal impairment.
Unhealthy behaviors such as smoking tobacco, drinking alcohol, and a sedentary lifestyle are
considered risk factors of CKD. CKD shares these risk factors with cardiovascular diseases and
some cancers. Most patients with CKD die of those diseases; some of them progress to end-stage
renal disease. Recent studies have reported that CKD was associated with oxidative stress and chronic
inflammation [2]. In addition, oxidative stress and inflammation link CKD with atherosclerotic
cardiovascular diseases [2]. Recently, the roles of inflammation and oxidative stress on CKD
development and progression have been highlighted [16]. Oxidative stress, such as iron overload,
can increase the inflammatory response, such as TNF-α and its receptors, adhesion molecules, and
chemokine expression. The increased pro-inflammatory response interacts to stimulate oxidative stress.
This interaction between oxidative stress and inflammation may have a synergistic effect on CKD
development and progression. Ferritin can be considered a surrogate marker of oxidative stress and
inflammation, but it cannot be considered to be their direct stimulator. In addition to iron overload as
Int. J. Environ. Res. Public Health 2016, 13, 1058 6 of 9
an indicator of oxidative stress, we used ferritin to represent the inflammatory status in CKD patients.
This dual representativeness of ferritin can be a useful additional marker for the prediction of CKD.
Oxidative stress is a byproduct of aerobic respiration during mammalian energy production
in the mitochondria. An oxidative environment in the body is also produced by iron overload and
enzymatic or non-enzymatic sources such as nicotinamide dinucleotide (phosphate). Iron ions, directly
or indirectly, interact with reactive oxygen species through oxidation-reduction and radical scavenging
mechanisms. Iron in blood binds to transferrin for transport to various tissues. After transport, iron
enters cells by means of the transferrin receptor, and excess iron is stored and regulated by ferritin [17].
Iron-related oxidative stress can catalyze the conversion of superoxide and hydrogen peroxide to more
potent oxidants, such as hydroxyl radicals or ferryl or perferryl species, by Fenton-type reactions [18].
Additionally, iron activates NF-kB, resulting in TNF-α and macrophage inflammatory protein-1.
Chronic iron overload in animal models decreases antioxidant activity, such as glutathione peroxidase,
and increases lipid peroxidation, causing the oxidation of proteins and nucleic acids [19]. Young et al.
reported that patients with hereditary hemochromatosis have reduced levels of antioxidant activity
and increased lipid peroxidation [20]. Based on previous studies using animal and human models,
iron overload can result in lipid, protein, and nucleic acid peroxidation and in reactive oxygen species
in the circulation. Excessive iron causes endothelial dysfunction and inflammation. Oxidative stresses
such as excessive iron are associated with diabetes mellitus, hypertension and dyslipidemia and
may accelerate renal injury and dysfunction [2]. Ferritin as a surrogate marker of body iron levels,
and inflammatory reactions can be considered as a pathophysiologic bridge among oxidative stress,
inflammation, and CKD.
Chronic low-grade inflammation is identified as an integral part of the pathogenesis of CKD,
although the precise mechanisms between inflammation and CKD have not yet been elucidated.
Previous studies have shown that elevated white blood cell count and C-reactive protein level are
associated with CKD and its progression [21,22]. Systemic inflammation causes the reduced production
of nitric oxide (NO) and increased activity of the renin-angiotensin system, leading to endothelial
dysfunction [2]. Reduced NO as an endogenous vasodilator contributes to the progression of renal
damage. Furthermore, various pro-inflammatory cytokines exacerbate the progression of CKD.
Ferritin is the main iron storage protein in human and is classified into two types: L-ferritin,
from the liver, promotes iron nucleation, mineralization and long-term storage; H-ferritin, from the
heart, plays a role in detoxifying iron and is regulated by cytokines and hormones [23]. Body iron
is primarily stored in the form of ferritin, which can surround and carry about 4000–4500 iron
atoms. Serum ferritin concentrations are positively correlated with total body iron levels if acute
inflammation is absent. Its measurement specifically represents body iron level. Exposure to excess
iron results in expression of L-ferritin mRNA, while chelation of iron using defoxamine decreases
L-ferritin mRNA level. The regulatory system of ferritin is sensitive to general oxidative status in
addition to iron level [24]. As ferritin is an acute phase protein, its level is elevated under acute and
chronic inflammatory environments, independent of iron status. The H-ferritin gene is expressed by
pro-inflammatory cytokines such as tumor necrosis factor-α and interferon-γ [25]. Thus, ferritin is
can be used as a surrogate marker and connecting link between iron storage and inflammatory status.
High ferritin level implicates iron overload, resulting in oxidative stress, and also reflects inflammation.
In addition, previous studies have reported that ferritin levels were associated with higher risk of
cerebro-/cardio-vascular diseases, infection and mortality in hemodialysis patients [11,26].
The World Health Organization has suggested that the cut-off point of ferritin value by sex
varies as 15 ng/mL for iron depletion in both sexes and 200 ng/mL in men and 150 ng/mL in
women for iron excess [12]. To exclude subjects with anemia due to iron deficiency or chronic disease,
we excluded participants with ferritin <15 ng/mL. While the cut-off ferritin level for men was higher
than for women, the percentage of individuals in the high-ferritin group is higher in men than
women (15.1% vs. 3.6%). In addition, men in the high-ferritin group exhibited unhealthier behaviors,
such as high-risk drinking, cigarette-smoking, and physical inactivity, compared to the men in the
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normal-ferritin group, while the unhealthy behaviors of the women were not significantly different
between the two groups. Unhealthier behaviors in men would have an additive effect on the higher
risk of CKD prevalence.
Some limitations should be taken into account when interpreting this work. First, we may
not conclude that higher ferritin level causes CKD based on this cross-sectional design; however,
we can expect to draw the relationship between higher ferritin level and CKD by performing
prospective cohort study. Interpretation of our results should consider its limitations with regard
to drawing conclusions on any causal relationships between ferritin levels and CKD prevalence.
Further longitudinal studies are warranted to better clarify this causal relationship. Second, the Kidney
Disease Outcomes Quality Initiative guidelines [27] define CKD as the presence of either low eGFR
or proteinuria lasting for at least three months. Because we used a single measurement of eGFR and
proteinuria, we cannot confirm that they lasted for three month or more. Furthermore, the MDRD
formula was used to define CKD as an eGFR less than 60 mL/1.73m2, rather than actually measuring
the GFR. The MDRD formula was developed for people of European descents. Unfortunately, there is
no equation to estimate GFR for Koreans. If a formula for the estimation of GFR in Korean population
was available, we could more accurately analyze this association. Third, urine analyses were not based
on the first morning urine samples. In addition, proteinuria was examined using dipstick methods
rather than albuminuria measured by 24-h urine collection or albumin-to-creatinine ratio. Even though
the Kidney Disease Improving Global Outcomes (KDIGO) guideline recommends the measurement
of albuminuria for the evaluation of CKD, they allow the use of proteinuria measured by dipstick
methods. Fourth, we could not classify ferritin into L-ferritin and H-ferritin. Thus, we do not know
which form of ferritin is mainly associated with CKD prevalence. Fifth, an inadequate number of
high-ferritin women and a low cut-off point for ferritin might have made it difficult to determine the
effect of ferritin on CKD in women.
Despite these potential limitations, this study has several strengths. We preserved the
representativeness of the Korean population because all analyses were conducted using data based on
the 2010–2012 KNHANES after sampling weighting was applied. Ferritin level is easily measured in a
clinical setting and is a surrogate marker reflective of oxidative stress and inflammation. Body ferritin
level is rarely influenced by sea level or tobacco-smoking behavior.
5. Conclusions
In conclusion, serum ferritin concentrations seem to be associated with a higher risk of CKD
in men but not in women, after adjustment for age, energy intake, drinking status, smoking status,
physical activity status, BMI, fasting plasma glucose, cholesterol, and ALT. Ferritin concentration
is one of the laboratory tests used in clinical settings to detect iron deficiency or overload. If a
physician recognizes that his/her patients have high ferritin levels in the absence of acute inflammation,
the doctor can recommend modification of risk factors, such as obesity, hypertension, dyslipidemia,
and hyperglycemia, and eventually prevent CKD and its comorbidities.
Supplementary Materials: The following are available online at www.mdpi.com/1660-4601/13/11/1058/s1,
Table S1. Logistic regression analyses for CKD of various risk factors.
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